Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2026-03-20 @ 8:07 PM
Study NCT ID:
NCT01522469
Status:
COMPLETED
Last Update Posted:
2024-01-30
First Post:
2012-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Sponsor:
Arog Pharmaceuticals, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ARO-004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None